But analysts say the drug price talks will likely have a muted financial impact on manufacturers, at least for this first round of prescription medicines.
More broadly, some of the drugs on the list aren't significant contributors to their company's business in the first place.
"The commercial impact of negotiations appears limited in the near term for this initial list of drugs," Mara Goldstein, managing director of Mizuho Securities, told CNBC.
The list names drugs with the highest spending for Medicare Part D, which covers prescription medications, from June 2022 to May 2023.
Several drugmakers, including a handful whose medications are on the list, have filed lawsuits in different federal courts seeking to stop the negotiations.
Persons:
Eliquis, Mara Goldstein, Biden, Johnson, there's
Organizations:
New, Halsted Pharmacy, Medicare, Mizuho Securities, CNBC, Myers Squibb, Johnson, Merck, AstraZeneca, Supreme, U.S . Chamber of Commerce
Locations:
Chicago , Illinois, Bristol, U.S